Table 1.
Macrophages targeting therapies.
| Category | Substance | Target site | Mechanisms of action |
|---|---|---|---|
| Inhibitor | Zoledronic acid | CCL2 | Suppress the expression of CCL2 |
| Gefitinib | CCL5 | Decrease the secretion of CCL5 | |
| PLX3397 | CSF1R | Inhibit the expression of CSF1R | |
| GW2580 | CSF1 | Inhibit the expression of CSF1 | |
| Wortmannin | PI3K | Decrease serum cytokine levels by inhibiting PI3K | |
| Monoclonal antibody or blocker | HAC | PD-L1 | Block human PD-L1 |
| BMS-936558 | PD-1 | Block the interaction between PD-1 and PD-L1 | |
| Hu5F9-G4 | CD47 | Bock CD47 that induces tumor-cell phagocytosis | |
| KWAR23 | SIRPα | Combined with tumor-opsonizing antibodies to augment neutrophils and TAMs antitumor activity | |
| GHI/75 | LILRB1 | Bock the MHC I/LILRB1 signaling way | |
| Trabectedin | Macrophages | Block the immunosuppressive effect | |
| Immunomodulator linemode | Macrophages | Block the activity of macrophages in tumor angiogenesis | |
| Biological response modifier | DNMTi 5-Azacytidine (AZA) | Macrophages | Regulate of macrophages polarization |
| α-Difluoromethylornithine (DFMO) | Macrophages | Regulate of macrophages polarization | |
| Dual-inhibitor-loaded nanoparticles (DNTs) | M2 macrophages | Make M2 macrophages repolarize to active M1 macrophages and inhibit CSF1R and SHP-2 |
In this table, we summarize the relevant macrophages targeting therapies mentioned in chapter 5 about anti-tumor cells. It divides the drugs into inhibitor, monoclonal antibody, or blocker and biological response modifier, and in each category, it contains substance, target site, and mechanisms of action of these drugs.